Karo Bio’s Capital Markets Day in London

Karo Bio’s Capital Markets Day in London

Karo Bio, a leading international drug discovery company focusing on
nuclear receptors as drug targets, will today present an overview of the
Company for investors and analysts at a Capital Markets Day in London.
The management team, led by President Björn Nilsson, will summarize Karo
Bio’s business and financial strategies as well as updating investors
and analysts on progress in the Company’s product pipeline and key
technologies.

Karo Bio is currently collaborating with four of the eleven largest
pharmaceutical companies in the world, and anticipates forming similar
alliances with other industry leaders based on its world-leading
technologies. .

The presentations, which follow a similar event in Stockholm on March 6,
will outline progress on the Company’s key partnered projects and
highlight expected news flow during the year.

Björn Nilsson, President of Karo Bio, commented:

“We are delighted to have the opportunity to provide analysts and
investors with a better understanding of our products and technologies
and the many outstanding business opportunities which are open to us.”

Management PowerPoint Presentations will be available on the Karo Bio
web site from Friday May 17.

For further information, please contact:

Per Otteskog, Senior Vice President
Tel +46-8-608 6018
Mobile: +46-70-632 75 27

Jonathan Birt/Mo Noonan, Financial Dynamics
Tel +44-20-7831-3113

Background
Karo Bio has operations in Sweden and the United States. The Company
employs 140 people.

Karo Bio has been listed on the Stockholm stock exchange (Reuters:
KARO.ST) since 1998 and maintains a leading position in the field of
drug discovery focused on nuclear receptors. Nuclear receptors are
validated drug targets for a number of clinical indications and the
Company uses proprietary technologies for the development of novel and
improved therapies for major markets. Karo Bio has 400 patent cases
including 128 granted patents.

Karo Bio has drug discovery programs in several therapeutic areas
including men’s and women’s health care, metabolic disorders such as
obesity, cardiovascular disease, diabetes, dermatology and
ophthalmology.

Karo Bio collaborates with major pharmaceutical companies for the
development of products and marketing. In these partnerships Karo Bio
receives upfront payments, R&D funding and milestone payments, as well
as royalties on net sales when products reach the market.

Karo Bio has strategic pharmaceutical drug discovery partnerships with
Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Inc. and Wyeth
Pharmaceuticals.

————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.waymaker.net/bitonline/2002/05/16/20020516BIT00010/wkr0001.doc
https://www.waymaker.net/bitonline/2002/05/16/20020516BIT00010/wkr0002.pdf